Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMISKJ9)

• Drug Name: SRPIN-340 Drug Info
• Synonyms: SRPIN340; 218156-96-8; SRPIN 340; N-(2-(Piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide; SRPIN-340; N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide; N-[2-(Piperidin-1-yl)-5-(trifluoromethyl)phenyl]pyridine-4-carboxamide; C18H18F3N3O; N-[2-piperidin-1-yl-5-(trifluoromethyl)phenyl]pyridine-4-carboxamide; 4-Pyridinecarboxamide, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-; AC1MDY5L; SCHEMBL1110476; SYN5233; EX-A208; AOB1635; MolPort-002-890-093; DWFGGOFPIISJIT-UHFFFAOYSA-N; HMS3653I06
• Cross-matching ID:
  PubChem CID: 2797577
  ChEBI ID: CHEMBL4064277
  TTD Drug ID: D0V4JW

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Graft-versus-host disease	2.15	0.00e+0	32/42 (76.19%)	HLA-DRB1;HLA-DRA;CD86;...
Inflammatory bowel disease	2.14	0.00e+0	58/65 (89.23%)	TLR4;HLA-DRB1;HLA-DRA;...
Primary bile acid biosynthesis	2.11	0.00e+0	15/17 (88.24%)	AMACR;AKR1C4;CYP27A1;...
Phagosome	2.08	0.00e+0	118/152 (77.63%)	TLR4;THBS1;CD36;...
Steroid hormone biosynthesis	2.01	0.00e+0	43/61 (70.49%)	HSD11B1;UGT2B4;UGT2B28;...
Allograft rejection	1.99	1.48e-3	32/38 (84.21%)	CD40;HLA-DRB1;HLA-DRA;...
Metabolism of xenobiotics by cytochrome P450	1.94	1.27e-3	49/77 (63.64%)	GSTO1;HSD11B1;UGT2B4;...
Malaria	1.93	1.11e-3	44/50 (88%)	TLR4;THBS1;CD36;...
Leishmaniasis	1.88	2.96e-3	67/77 (87.01%)	TLR4;HLA-DRB1;HLA-DRA;...
Antigen processing and presentation	1.84	3.55e-3	60/78 (76.92%)	HLA-DRB1;HLA-DRA;CD74;...
Toll-like receptor signaling pathway	1.83	3.23e-3	94/104 (90.38%)	TLR4;CD40;LY96;...
Hematopoietic cell lineage	1.83	2.96e-3	90/99 (90.91%)	CD36;CD59;HLA-DRB1;...
Type I diabetes mellitus	1.78	1.37e-2	38/43 (88.37%)	HLA-DRB1;HLA-DRA;CD86;...
Rheumatoid arthritis	1.75	1.65e-2	78/93 (83.87%)	TLR4;HLA-DRB1;HLA-DRA;...
Retinol metabolism	1.74	1.66e-2	41/68 (60.29%)	ALDH1A1;RDH11;UGT2B4;...
Neutrophil extracellular trap formation	1.71	2.99e-2	101/189 (53.44%)	TLR4;C5AR1;AQP9;...
Basal transcription factors	1.71	2.82e-2	37/45 (82.22%)	TAF7;TAF9B;GTF2B;...
Oxidative phosphorylation	1.70	3.01e-2	93/133 (69.92%)	ATP6V1D;ATP6V1B2;ATP6V1C1;...
Folate biosynthesis	1.69	3.04e-2	23/26 (88.46%)	PAH;GGH;MOCS2;...
Ribosome	1.69	2.93e-2	113/158 (71.52%)	MRPL13;MRPS16;RPL36;...
Staphylococcus aureus infection	1.69	2.87e-2	72/95 (75.79%)	C5AR1;HLA-DRB1;KRT13;...
Legionellosis	1.67	3.23e-2	51/57 (89.47%)	TLR4;SAR1B;TLR2;...
Autoimmune thyroid disease	1.66	3.32e-2	46/53 (86.79%)	CD40;HLA-DRB1;HLA-DRA;...
Pentose and glucuronate interconversions	1.64	3.70e-2	17/34 (50%)	DCXR;UGT2B4;UGT2B28;...
Protein digestion and absorption	-1.88	3.45e-2	78/103 (75.73%)	COL11A2;CTRB2;COL9A1;...
Mucin type O-glycan biosynthesis	-1.95	2.30e-2	20/36 (55.56%)	GALNT12;GALNT11;GCNT1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	24H	Hide ▲